When was AIRNA founded?

AIRNA was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is AIRNA located?

AIRNA is headquartered in Cambridge, United States.

How many employees does AIRNA have?

As of Jun 30, 2026, the latest employee count at AIRNA is 84.

Is AIRNA a funded company?

AIRNA is a funded company, having raised a total of $245M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 19, 2023.

When was the latest funding round of AIRNA?

AIRNA's latest funding was a $***** Series B round on Apr 01, 2025, with participation from 6 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.35B in funding in 2026 to date.

Where does AIRNA rank among its competitors?

AIRNA ranks 34th amongst 619 active competitors, of which 226 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of AIRNA?

AIRNA's top competitors include Alnylam, Spark Therapeutics and BioMarin Pharmaceutical. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

AIRNA - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of gene therapies for rare and common diseases. It offers RNA editing therapeutics based on a platform RESTORE+ to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD).

Website: airna.com
Email ID: *****@airna.com

Key Metrics

Founded Year

2021

Location

Cambridge, United States

Stage

Series B

Total Funding

$245M in 3 rounds

Latest Funding Round

Series B, Apr 01, 2025, $*****

Investors

Forbion & 10 more

Ranked

34^th among 619 active competitors

Employee Count

84 as on Jun 30, 2026

Similar Companies

Alnylam & 770 more

View AIRNA's full profile

AIRNA has raised a total funding of $245M over 3 rounds. Its first funding round was on Sep 19, 2023. Its latest funding round was a Series B round on Apr 01, 2025 for $*****. 6 investors participated in its latest round. AIRNA has 11 institutional investors.

Here is the list of recent funding rounds of AIRNA:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 01, 2025	5330449	Series B	1620102	4061767	7257810	3921275
Jul 31, 2024	4225185	Series A	3720348	3724836	1351082	Ono Venture Investment & 3 more
Sep 19, 2023	1883147	Series A	6141974	4322883	Arch Venture Partners	ND Capital & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of AIRNA's funding rounds and investors

The founders of AIRNA are Thorsten Stafforst, Jin Billy Li and Paul Vogel.

Here are the details of AIRNA's key team members:

Thorsten Stafforst: Co-Founder of AIRNA.
Jin Billy Li: Co-Founder of AIRNA.
Paul Vogel: Former Co-Founder of AIRNA.

View details of AIRNA's Founder profiles and Board Members

AIRNA's employee count trend

AIRNA has 84 employees as of Jun 26. Here is AIRNA's employee count trend over the years:

Uncover AIRNA's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AIRNA include Alnylam, Spark Therapeutics and BioMarin Pharmaceutical. Here is the list of Top 10 competitors of AIRNA, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	BioMarin Pharmaceutical 1997, San Rafael (United States), Public	Developer of therapeutics for the treatment of rare genetic diseases	$37.5M	MPM Capital, Temasek & 7 others	72/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, MassChallenge & 19 others	70/100
7th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
8th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
9th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	T. Rowe Price, Fidelity Investments & 9 others	69/100
10th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
34th	AIRNA 2021, Cambridge (United States), Series B	Developer of gene therapies for rare and common diseases	$245M	RTW Investments, Nextech Invest & 9 others	63/100